Innovative drug companies compete for the second half

"It used to be a big booth of foreign companies, but now it is really different", a foreign company exclaimed during the CSCO (Chinese Society of Clinical Oncology Conference) in Xiamen this year. As he said, at this year's CSCO, the local booths represented by local innovative pharmaceutical companies have occupied most of the space in the venue: in addition to the "appearance", the most number of oral presentations released at the conference is also local innovative pharmaceutical companies - Baiji Shenzhou, although for Although the investment in innovative drugs has waned compared to the previous two years, the growth of China's local innovative drug companies can be seen for all to see.

After several years of R&D, a group of domestic head innovative drug companies have started to achieve the approval of innovative drugs on the market since the second half of 2018. Meanwhile, these companies have basically achieved IPO listing, and their R&D capability and pipeline level have basically been recognized by the capital market.